Oral traditional Chinese medicine for mild to moderate cases of COVID-19: a network meta-analysis based on RCTs.

IF 1.4 4区医学 Q4 INFECTIOUS DISEASES

Journal of Infection in Developing Countries Pub Date : 2024-11-30 DOI:10.3855/jidc.19398

Wen Cao, Nannan He, Yannian Luo, Zhiming Zhang

{"title":"Oral traditional Chinese medicine for mild to moderate cases of COVID-19: a network meta-analysis based on RCTs.","authors":"Wen Cao, Nannan He, Yannian Luo, Zhiming Zhang","doi":"10.3855/jidc.19398","DOIUrl":null,"url":null,"abstract":"Introduction: This systemic review examines the effectiveness and safety of combining traditional Chinese medicine with standard therapy in the treatment of mild to moderate cases of coronavirus disease 2019 (COVID-19).Methodology: We retrieved articles from PubMed, Web of Science, Cochrane, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, Weipi (VIP), and China Biology Medicine disc (CBM). The deadline for retrieval was 20 August 2022, and it was updated on 1 July 2023. Two researchers worked independently on literature screening, data extraction, and evaluation of the quality of the literature.Results: A total of 21 randomized controlled trials were included in this review; consisting of 9 articles in English and 12 articles in Chinese. According to the fixed-effects model, the results of the traditional meta-analysis indicated a significantly superior efficacy of oral traditional Chinese medicine combined with standard therapy in treating mild to moderate cases of COVID-19, compared to standard treatment (OR = 1.81, 95% CI: 1.59-2.06), with no increased adverse effects (OR = 1.28, 95% CI: 0.95-1.73). The network meta-analysis results revealed Lianhua Qingke, Toujie Quwen, and Jinhua Qinggan granules as the three best Chinese medicines with the most effective treatment outcomes; while Lianhua Qingwen capsule/granules, Reyanning, and Shufeng Jiedu capsules were the top three Chinese medicines with the fewest side effects.Conclusions: The efficacy of oral traditional Chinese medicine combined with standard therapy in treating mild to moderate COVID-19 was significantly superior to standard therapy alone. However, the limited quality of evidence reduces the reliability of the meta-analysis.","PeriodicalId":49160,"journal":{"name":"Journal of Infection in Developing Countries","volume":"18 11","pages":"1671-1681"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection in Developing Countries","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3855/jidc.19398","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This systemic review examines the effectiveness and safety of combining traditional Chinese medicine with standard therapy in the treatment of mild to moderate cases of coronavirus disease 2019 (COVID-19).

Methodology: We retrieved articles from PubMed, Web of Science, Cochrane, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, Weipi (VIP), and China Biology Medicine disc (CBM). The deadline for retrieval was 20 August 2022, and it was updated on 1 July 2023. Two researchers worked independently on literature screening, data extraction, and evaluation of the quality of the literature.

Results: A total of 21 randomized controlled trials were included in this review; consisting of 9 articles in English and 12 articles in Chinese. According to the fixed-effects model, the results of the traditional meta-analysis indicated a significantly superior efficacy of oral traditional Chinese medicine combined with standard therapy in treating mild to moderate cases of COVID-19, compared to standard treatment (OR = 1.81, 95% CI: 1.59-2.06), with no increased adverse effects (OR = 1.28, 95% CI: 0.95-1.73). The network meta-analysis results revealed Lianhua Qingke, Toujie Quwen, and Jinhua Qinggan granules as the three best Chinese medicines with the most effective treatment outcomes; while Lianhua Qingwen capsule/granules, Reyanning, and Shufeng Jiedu capsules were the top three Chinese medicines with the fewest side effects.

Conclusions: The efficacy of oral traditional Chinese medicine combined with standard therapy in treating mild to moderate COVID-19 was significantly superior to standard therapy alone. However, the limited quality of evidence reduces the reliability of the meta-analysis.

查看原文本刊更多论文

口服中药治疗轻、中度新冠肺炎：基于随机对照试验的网络meta分析

本系统综述探讨了中药结合标准疗法治疗轻中度冠状病毒病2019 （COVID-19）的有效性和安全性。方法：本文检索自PubMed、Web of Science、Cochrane、Embase、中国知网（CNKI）、万方、唯品（VIP）、中国生物医学光盘（CBM）。检索的截止日期是2022年8月20日，并于2023年7月1日更新。两位研究者独立进行文献筛选、数据提取和文献质量评估。结果：本综述共纳入21项随机对照试验；由9篇英文文章和12篇中文文章组成。根据固定效应模型，传统meta分析结果显示，口服中药联合标准疗法治疗轻中度新冠肺炎的疗效明显优于标准疗法（OR = 1.81, 95% CI: 1.59-2.06），不良反应无增加（OR = 1.28, 95% CI: 0.95-1.73）。网络荟萃分析结果显示，联花清咳、头结祛瘀、金花清肝颗粒是治疗效果最好的3种中药；而联花清温胶囊/颗粒、热炎宁和疏风解毒胶囊是副作用最小的前三名中药。结论：中药口服联合标准疗法治疗轻、中度新冠肺炎的疗效明显优于单纯标准疗法。然而，有限的证据质量降低了meta分析的可靠性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection in Developing Countries INFECTIOUS DISEASES-

CiteScore

3.70

自引率

5.30%

发文量

239

审稿时长

4-8 weeks

期刊介绍： The Journal of Infection in Developing Countries (JIDC) is an international journal, intended for the publication of scientific articles from Developing Countries by scientists from Developing Countries. JIDC is an independent, on-line publication with an international editorial board. JIDC is open access with no cost to view or download articles and reasonable cost for publication of research artcles, making JIDC easily availiable to scientists from resource restricted regions.